
Valnevas Lyme vaccine trial complets recruitment
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. announced that they have completed enrollment in the Vaccine Against Lyme for Outdoor...

BenevolentAI Ltd inks US$594m partnership with Merck KGaA
Under the licence agreement, BenevolentAI will identify and develop new compounds against three targets provided by Merck through hit identification...

Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment...

UK boosts AMR defenses with £30m PACE initiative
By bringing together funding, resources, and partnerships from its three notable partners Innovate UK, LifeArc, and Medicines Discovery Catapult...

UK publishes £2bn vision for engineering biology
Following extensive engagement with industry and stakeholders, the new "National Vision for Engineering Biology" lays out the government’s...

ViaNautis Bio Ltd closes US$25m Series A financing
The US$25m round of cambridge-based ViaNautis Bio Ltd, founded in 2018 as SomaServe, was led 4BIO Capital, BGF (both UK), and UCB Ventures (UK, US,...

Recordbreaking BIO-Europe in Munich, but: back to 2019
Record figures and a much better mood in Europe than one is currently hearing from the USA. Financing is difficult at the moment and the US...